For instance, prospective cohort trials examining ITLN1 expression in gastric cancer, hepatocellular carcinoma, and colorectal cancer using standardized immunohistochemical protocols are essential for ensuring reproducible and clinically meaningful results. The gene discussed is ITLN1; the disease is hepatocellular carcinoma.